Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Related to this article
Paul E. Oberstein, MD, discusses data for an autogene cevumeran–based regimen in pancreatic ductal adenocarcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
2
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
3
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
4
China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC
5